Entrada Therapeutics, Inc. — Q2 2023 Form 10-Q
Business context and reporting period. This unaudited filing covers the quarter and six months ended June 30, 2023. Entrada is a preclinical-stage biotechnology company developing Endosomal Escape Vehicle (EEV) therapeutics. It has no approved products and reported no product sales; its reported revenue to date is from its Vertex collaboration.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $18.2 million | None | $43.4 million | None |
| Research and development expense | $26.3 million | $16.2 million | $49.4 million | $32.0 million |
| General and administrative expense | $8.2 million | $7.3 million | $16.1 million | $13.8 million |
| Operating loss | $16.3 million | $23.6 million | $22.1 million | $45.7 million |
| Net loss | $25.9 million | $23.2 million | $32.6 million | $44.9 million |
| Net loss per share, basic and diluted | $0.78 | $0.74 | $0.99 | $1.43 |
Margins and profitability. Gross margin is not presented, and is not meaningful as a product-sales measure because the company has no product sales. The company remains loss-making. Q2 operating loss narrowed versus the prior-year quarter, but net loss increased, principally reflecting a $13.8 million income-tax provision related largely to the tax recognition of the Vertex payment.
Balance sheet and cash flow. At June 30, cash and cash equivalents were $79.7 million and marketable securities were $297.0 million, totaling $376.8 million in cash, cash equivalents and marketable securities. Current assets were $390.2 million and current liabilities $125.9 million. Six-month operating cash flow was positive $168.3 million, largely due to the Vertex upfront payment recorded in deferred revenue; investing cash flow was negative $153.7 million and financing cash flow positive $20.0 million. This operating cash inflow should not be interpreted as recurring operating profitability. The filing does not report borrowings or conventional financial debt. Operating lease liabilities totaled $73.0 million, separate from debt.
Collaboration and deferred revenue. Under the Vertex agreement, Entrada received a $223.7 million upfront payment and Vertex separately invested $26.3 million for 1,618,613 common shares. The agreement also provides for up to $485.0 million in research, development, regulatory and commercial milestones, plus tiered royalties in the mid-to-high single digits. At June 30, $197.2 million remained allocated to unsatisfied performance obligations and recorded as deferred revenue.
Material changes versus the prior comparable period
- Revenue began in 2023 under the Vertex agreement; $43.4 million was recognized in the first half, compared with none in 2022.
- First-half R&D expense rose $17.4 million, driven by higher internal personnel and facility costs, increased preclinical activity and a $2.8 million sublicense fee paid to Ohio State Innovation Foundation. Q2 R&D growth was particularly affected by ENTR-601-45 activity.
- First-half net loss improved by $12.2 million year over year, while Q2 net loss widened by $2.7 million, reflecting the quarter’s tax provision despite lower operating loss.
- Cash and marketable securities increased substantially from December 31, 2022, primarily following the Vertex transaction. Vertex’s equity investment also increased shares outstanding.
- Operating lease right-of-use assets increased following commencement of the approximately 10-year IDB facility lease in April 2023; the company recorded a $77.6 million right-of-use asset and a $63.6 million lease liability at commencement.
Outlook, commentary and key risks
- Management said June 30 liquidity, ongoing Vertex research support and anticipated Vertex milestones were expected to fund operations through 2025. The financial statements separately state that cash and marketable securities were expected to cover at least the next 12 months. Both estimates depend on assumptions; milestone payments are not assured.
- The FDA clinical hold on ENTR-601-44 remained in place. Entrada was working to provide requested information and expected a U.S. update in Q4 2023. The UK MHRA and Research Ethics Committee authorized a planned healthy-volunteer Phase 1 trial; first dosing was expected in September 2023, with data anticipated in the second half of 2024. These are forward-looking expectations, not reported outcomes.
- Management planned to submit an IND for ENTR-601-45 in Q4 2024. ENTR-701 is being advanced under the four-year Vertex research collaboration; Vertex holds an exclusive worldwide license and is responsible for development, manufacturing and commercialization beyond Entrada’s research work.
- The company expects continued operating losses, increasing R&D costs and a need for additional financing before any potential product revenue. Future equity financing could dilute shareholders; collaborations or licensing could require relinquishing rights.
- Key risks include the ENTR-601-44 clinical hold, the unproven EEV approach and absence of human clinical data, preclinical and clinical failure or delay, manufacturing and third-party supplier dependence, competition, and intellectual-property and funding risks. No material adverse legal proceeding was reported. Management concluded disclosure controls were effective as of June 30, 2023.
Important facts for investors to verify
- Whether the FDA clinical hold on ENTR-601-44 was resolved, and the status and results of the UK trial, against the timelines stated in this filing.
- Actual cash runway and operating spending compared with management’s through-2025 estimate, including whether anticipated Vertex milestones are achieved.
- How rapidly the $197.2 million of deferred collaboration revenue is recognized and how Vertex-funded research reimbursements compare with related costs.
- The size and timing of the $13.8 million quarterly and $17.4 million first-half income-tax provisions, and their cash impact.
- Future R&D spending, lease obligations and share dilution, including equity awards and the shares issued to Vertex.